반응식
[Cl:1][C:2]1[CH:3]=[C:4]([CH:7]=[CH:8][CH:9]=1)[CH:5]=O.[CH3:10][C:11](=O)[CH:12]=[CH2:13].[N:15]1([S:21]([C:24]2[CH:29]=[CH:28][C:27]([NH2:30])=[CH:26][CH:25]=2)(=[O:23])=[O:22])[CH2:20][CH2:19][CH2:18][CH2:17][CH2:16]1>>[Cl:1][C:2]1[CH:3]=[C:4]([C:5]2[N:30]([C:27]3[CH:28]=[CH:29][C:24]([S:21]([N:15]4[CH2:20][CH2:19][CH2:18][CH2:17][CH2:16]4)(=[O:23])=[O:22])=[CH:25][CH:26]=3)[C:11]([CH3:10])=[CH:12][CH:13]=2)[CH:7]=[CH:8][CH:9]=1참가 물질
4
실험 절차
3-Chlorobenzaldehyde and but-3-en-2-one were treated according to the procedure outlined in General Procedure C followed by subjecting the resulting product to conditions outlined in General Procedure D along with p-piperidinylsulfonyl phenylamine to obtain the titled compound. 1H NMR (CDCl3) δ ppm 1.42-1.65 (6H), 2.18 (3H), 3.00 (4H), 6.18 (1H), 6.40 (1H), 6.85-7.90 (8H); MS (ESI) m/z 415 (M+H).
출처 및 근거
- ORD 기록
- ord-2d32fddd135b41969e460b8bf3491573
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07741364B2
연결된 노트
불러오는 중…